leflunomide has been researched along with Adjuvant Arthritis in 25 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results demonstrate that topically applied leflunomide can be delivered effectively and deposited as teriflunomide in an arthritic joint, possibly allowing better compliance in rheumatoid arthritis patients by avoiding leflunomide's side effects." | 7.83 | Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. ( Bae, J; Park, JW, 2016) |
| "To investigate the effects of leflunomide (LEF) on modulating interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor- alpha (TNF-alpha) production induced by lipopolysaccharide (LPS) in peritoneal macrophages (PMphi) in adjuvant arthritis rats and elucidate the possible mechanisms of antiinflammatory and antirheumatoid effects of LEF." | 7.71 | Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats. ( Li, WD; Lin, ZB; Ran, GX; Teng, HL, 2002) |
| "To observe the effects of leflunomide (LEF), an isoxazole immunomodulatory agent and its active metabolite, A771726, on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis rats and to further investigate the immunosuppression effects of leflunomide and its mechanisms." | 7.71 | [Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats]. ( Li, WD; Lin, ZB, 2002) |
| "Leflunomide is a low-molecular-weight compound that is widely used in the treatment of rheumatoid arthritis." | 3.85 | The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1. ( Cho, ML; Jhun, JY; Kim, EK; Lee, HJ; Lee, WS; Min, JK; Moon, SJ; Park, SH, 2017) |
| "These results demonstrate that topically applied leflunomide can be delivered effectively and deposited as teriflunomide in an arthritic joint, possibly allowing better compliance in rheumatoid arthritis patients by avoiding leflunomide's side effects." | 3.83 | Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model. ( Bae, J; Park, JW, 2016) |
| "Nimesulide is a COX-2 inhibitor used for symptomatic relief of rheumatoid arthritis." | 3.80 | Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis. ( Abdel-Naim, AB; Al-Abbasi, FA; Al-Abd, AM; El-Eraky, WI; Khalifa, AE; Nagy, AA; Nofal, SM; Williams, RO, 2014) |
| "Iguratimod, a novel disease-modifying antirheumatic drug, which is now used in clinics in China and Japan, has been confirmed as a highly efficacious and safe drug for rheumatoid arthritis therapy." | 3.79 | A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. ( Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q, 2013) |
| "To investigate the effects of leflunomide (LEF) on modulating interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor- alpha (TNF-alpha) production induced by lipopolysaccharide (LPS) in peritoneal macrophages (PMphi) in adjuvant arthritis rats and elucidate the possible mechanisms of antiinflammatory and antirheumatoid effects of LEF." | 3.71 | Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats. ( Li, WD; Lin, ZB; Ran, GX; Teng, HL, 2002) |
| "To observe the effects of leflunomide (LEF), an isoxazole immunomodulatory agent and its active metabolite, A771726, on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis rats and to further investigate the immunosuppression effects of leflunomide and its mechanisms." | 3.71 | [Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats]. ( Li, WD; Lin, ZB, 2002) |
| " This study compared groups treated with high-dose methotrexate (MTX)/leflunomide (LEF) and CP-25 combined with low-dose MTX/LEF in an adjuvant-induced arthritis (AA) rat model and investigated possible mechanisms." | 1.51 | CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation. ( Chang, Y; Jia, X; Wang, C; Wei, W; Wu, Y; Yang, X; Zhang, L; Zhao, Y, 2019) |
| " From the day of arthritis onset, rats were treated daily by gavage with leflunomide (Lef) or ART at a dosage of 10 mg/kg/d or 5 mg/kg/d, respectively, for 16 days." | 1.39 | Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. ( Chen, G; Huang, H; Li, C; Li, Y; Lin, S; Lin, W; Liu, P; Shen, W; Shen, X; Wang, S; Wang, Y; Zhou, C, 2013) |
| " Drug studies were performed, using a 4-day dosing schedule, on optimal DTH elicited on day 10, suboptimal DTH elicited on day 15, and AA (day 16)." | 1.28 | Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. ( Hambleton, P; McMahon, S, 1990) |
| "), dosed for 8 or 16 days beginning with the day of adjuvant administration, significantly reduced edema, fibrinogen levels, and erythrocyte sedimentation rates (ESR) 42 days later." | 1.27 | Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. ( Buyniski, JP; Gylys, JA; Pasternak, RD; Siminoff, P; Wadopian, NS; Wright, RN, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (12.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 4 (16.00) | 29.6817 |
| 2010's | 14 (56.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuo, EA | 1 |
| Hambleton, PT | 1 |
| Kay, DP | 1 |
| Evans, PL | 1 |
| Matharu, SS | 1 |
| Little, E | 1 |
| McDowall, N | 1 |
| Jones, CB | 1 |
| Hedgecock, CJ | 1 |
| Yea, CM | 1 |
| Chan, AW | 1 |
| Hairsine, PW | 1 |
| Ager, IR | 1 |
| Tully, WR | 1 |
| Williamson, RA | 1 |
| Westwood, R | 1 |
| Manolios, N | 1 |
| Hou, G | 1 |
| El-Sheikh, SMA | 1 |
| Abd El-Alim, AEF | 1 |
| Galal, AAA | 1 |
| El-Sayed, RG | 1 |
| El-Naseery, NI | 1 |
| Liang, C | 1 |
| Li, J | 2 |
| Lu, C | 1 |
| Xie, D | 1 |
| Liu, J | 1 |
| Zhong, C | 1 |
| Wu, X | 2 |
| Dai, R | 1 |
| Zhang, H | 1 |
| Guan, D | 1 |
| Guo, B | 1 |
| He, B | 1 |
| Li, F | 1 |
| He, X | 1 |
| Zhang, W | 1 |
| Zhang, BT | 1 |
| Zhang, G | 1 |
| Lu, A | 1 |
| Yang, X | 1 |
| Zhao, Y | 1 |
| Jia, X | 1 |
| Wang, C | 1 |
| Wu, Y | 1 |
| Zhang, L | 1 |
| Chang, Y | 1 |
| Wei, W | 1 |
| Luo, Q | 1 |
| Sun, Y | 1 |
| Liu, W | 1 |
| Qian, C | 1 |
| Jin, B | 1 |
| Tao, F | 1 |
| Gu, Y | 1 |
| Shen, Y | 1 |
| Xu, Q | 1 |
| Al-Abd, AM | 1 |
| Al-Abbasi, FA | 1 |
| Nofal, SM | 1 |
| Khalifa, AE | 1 |
| Williams, RO | 1 |
| El-Eraky, WI | 1 |
| Nagy, AA | 1 |
| Abdel-Naim, AB | 1 |
| Bae, J | 1 |
| Park, JW | 1 |
| Gowayed, MA | 1 |
| Refaat, R | 1 |
| Ahmed, WM | 1 |
| El-Abhar, HS | 1 |
| El-Setouhy, DA | 1 |
| Abdelmalak, NS | 1 |
| Anis, SE | 1 |
| Louis, D | 1 |
| Gao, HY | 1 |
| Luo, J | 1 |
| Li, XF | 1 |
| Lv, Q | 1 |
| Wen, HY | 1 |
| Song, QZ | 1 |
| Zhao, WP | 1 |
| Zhao, XC | 1 |
| Zhang, TT | 1 |
| Zhang, SY | 1 |
| Zhi, JM | 1 |
| Moon, SJ | 1 |
| Kim, EK | 1 |
| Jhun, JY | 1 |
| Lee, HJ | 1 |
| Lee, WS | 1 |
| Park, SH | 1 |
| Cho, ML | 1 |
| Min, JK | 1 |
| Wang, TY | 1 |
| Li, CY | 1 |
| Jin, Y | 1 |
| Lü, XW | 1 |
| Wang, XH | 1 |
| Zhou, Q | 1 |
| Yamaguchi, T | 1 |
| Kakefuda, R | 1 |
| Tanimoto, A | 1 |
| Watanabe, Y | 1 |
| Tajima, N | 1 |
| Li, Y | 2 |
| Wang, S | 1 |
| Wang, Y | 1 |
| Zhou, C | 1 |
| Chen, G | 1 |
| Shen, W | 1 |
| Li, C | 1 |
| Lin, W | 1 |
| Lin, S | 1 |
| Huang, H | 1 |
| Liu, P | 1 |
| Shen, X | 1 |
| Yao, Y | 1 |
| Ding, CZ | 1 |
| Fang, Y | 1 |
| Li, WD | 2 |
| Ran, GX | 1 |
| Teng, HL | 1 |
| Lin, ZB | 2 |
| Wei, YH | 1 |
| Qiang, CJ | 1 |
| Oliushin, IuA | 1 |
| Smith-Oliver, T | 1 |
| Noel, LS | 1 |
| Stimpson, SS | 1 |
| Yarnall, DP | 1 |
| Connolly, KM | 1 |
| Hambleton, P | 1 |
| McMahon, S | 1 |
| Hirschelmann, R | 1 |
| Schade, R | 1 |
| Pasternak, RD | 1 |
| Wadopian, NS | 1 |
| Wright, RN | 1 |
| Siminoff, P | 1 |
| Gylys, JA | 1 |
| Buyniski, JP | 1 |
| Bartlett, RR | 1 |
| Schleyerbach, R | 1 |
1 review available for leflunomide and Adjuvant Arthritis
| Article | Year |
|---|---|
[Basic therapy of rheumatoid arthritis with leflunomide (review)].
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Female; Humans; Isoxazoles; Leflunomide; Ma | 2004 |
24 other studies available for leflunomide and Adjuvant Arthritis
| Article | Year |
|---|---|
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Topics: Acrylamides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Dihydroorota | 1996 |
Anti-inflammatory Effects of First-line Anti-arthritic Drugs on T-cell Activation.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Cytokines; Leflunomide; Mice; Th1 Cells; | 2023 |
Anti-arthritic effect of β-caryophyllene and its ameliorative role on methotrexate and/or leflunomide-induced side effects in arthritic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Arthritis, Experi | 2019 |
HIF1α inhibition facilitates Leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis.
Topics: Acriflavine; Adult; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Aryl Hydrocarbon Recept | 2019 |
CP-25 combined with MTX/ LEF ameliorates the progression of adjuvant-induced arthritis by the inhibition on GRK2 translocation.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Cells, Cultured; Disease Progression; Drug T | 2019 |
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthri | 2013 |
Nimesulide improves the symptomatic and disease modifying effects of leflunomide in collagen induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Synergism; Drug | 2014 |
Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental | 2016 |
Effect of galantamine on adjuvant-induced arthritis in rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Biomarkers; Dose-Response Relationship, | 2015 |
Leflunomide biodegradable microspheres intended for intra-articular administration: Development, anti-inflammatory activity and histopathological studies.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Chemistry, Pharmac | 2015 |
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Collagen Type II; Cyclophosphamide; Drug The | 2015 |
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid | 2017 |
Leflunomide induces immunosuppression in collagen-induced arthritis rats by upregulating CD4+CD25+ regulatory T cells.
Topics: Adjuvants, Immunologic; Animals; Arthritis, Experimental; Cattle; CD4 Antigens; Immunosuppressive Ag | 2010 |
Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Col | 2012 |
Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway.
Topics: Animals; Antimalarials; Antirheumatic Agents; Artemisinins; Artesunate; Arthritis, Experimental; Art | 2013 |
Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone and Bones; Cell Survival; Cells, Cu | 2013 |
Dynamic effects of leflunomide on IL-1, IL-6, and TNF-alpha activity produced from peritoneal macrophages in adjuvant arthritis rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Female; Interleukin-1; In | 2002 |
[Effects of leflunomide and its active metabolite on the production and mRNA expression of TNF-alpha in peritoneal macrophages and synovial cells with adjuvant arthritis in rats].
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; C | 2002 |
Effects and mechanisms of FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor, on adjuvant arthritis in rats.
Topics: Animals; Arthritis, Experimental; Body Weight; Cell Proliferation; China; Disease Models, Animal; Do | 2004 |
Elevated levels of TNF in the joints of adjuvant arthritic rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Biological Assay; Cells, | 1993 |
Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Art | 1990 |
6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.
Topics: Acute-Phase Reaction; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experi | 1988 |
Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Experimental; Cyclosporins; | 1987 |
Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity--I. Disease modifying action on adjuvant arthritis of the rat.
Topics: Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Cyclophosphamide; Immunosuppr | 1985 |